Literature DB >> 10955845

Polyisobutylcyanoacrylate nanocapsules containing an aqueous core as a novel colloidal carrier for the delivery of oligonucleotides.

G Lambert1, E Fattal, H Pinto-Alphandary, A Gulik, P Couvreur.   

Abstract

PURPOSE: The goal of the present paper was to encapsulate oligonucleotides in a new particulate carrier in order to protect them from enzymatic degradation.
METHODS: Nanocapsules with an aqueous core containing oligonucleotides were prepared by interfacial polymerization of isobutylcyanoacrylate in a W/O emulsion. Ultracentrifugation and re-suspension in water yielded a dispersion of these containing an aqueous core nanocapsules. Zeta potential measurements and quenching of fluorescence of fluorescein-bounded oligonucleotides were used to study the localization of the oligonucleotides. Oligonucleotide degradation studies were carried out in fetal calf serum.
RESULTS: Polydisperse nanocapsules of size ranging from 20 to 400 nm were obtained. Oligonucleotide loading did not significantly influence the zeta potential, suggesting they were located within the core of the nanocapsules. Fluorescence quenching assays confirmed this localization. When encapsulated in the nanocapsules and incubated in the presence of serum, the oligonucleotides were efficiently protected from degradation by nucleases, whereas oligonucleotides adsorbed onto nanospheres were protected less efficiently.
CONCLUSIONS: This paper describes, for the first time, a nanotechnology able to encapsulate oligonucleotides rather than adsorbing them at the surface of a solid support. Such a formulation has great potential for oligonucleotide delivery.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10955845     DOI: 10.1023/a:1007582332491

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  26 in total

1.  The multiple inhibitory mechanisms of GEM 91, a gag antisense phosphorothioate oligonucleotide, for human immunodeficiency virus type 1.

Authors:  K Yamaguchi; B Papp; D Zhang; A N Ali; S Agrawal; R A Byrn
Journal:  AIDS Res Hum Retroviruses       Date:  1997-05-01       Impact factor: 2.205

2.  Solute perturbation of protein fluorescence. The quenching of the tryptophyl fluorescence of model compounds and of lysozyme by iodide ion.

Authors:  S S Lehrer
Journal:  Biochemistry       Date:  1971-08-17       Impact factor: 3.162

3.  Spongelike alginate nanoparticles as a new potential system for the delivery of antisense oligonucleotides.

Authors:  I Aynié; C Vauthier; H Chacun; E Fattal; P Couvreur
Journal:  Antisense Nucleic Acid Drug Dev       Date:  1999-06

4.  Cationic liposome-encapsulated antisense oligonucleotide mediates efficient killing of intracellular Leishmania.

Authors:  R Chakraborty; D Dasgupta; S Adhya; M K Basu
Journal:  Biochem J       Date:  1999-06-01       Impact factor: 3.857

5.  Inhibition of growth of human tumor cell lines in nude mice by an antisense of oligonucleotide inhibitor of protein kinase C-alpha expression.

Authors:  N Dean; R McKay; L Miraglia; R Howard; S Cooper; J Giddings; P Nicklin; L Meister; R Ziel; T Geiger; M Muller; D Fabbro
Journal:  Cancer Res       Date:  1996-08-01       Impact factor: 12.701

6.  Definition by specific antisense oligonucleotides of a role for protein kinase C alpha in expression of differentiation markers in normal and neoplastic mouse epidermal keratinocytes.

Authors:  Y S Lee; A A Dlugosz; R McKay; N M Dean; S H Yuspa
Journal:  Mol Carcinog       Date:  1997-01       Impact factor: 4.784

7.  Degradation of poly (isobutyl cyanoacrylate) nanoparticles.

Authors:  V Lenaerts; P Couvreur; D Christiaens-Leyh; E Joiris; M Roland; B Rollman; P Speiser
Journal:  Biomaterials       Date:  1984-03       Impact factor: 12.479

8.  Preparation and characterization of nanocapsules from preformed polymers by a new process based on emulsification-diffusion technique.

Authors:  D Quintanar-Guerrero; E Allémann; E Doelker; H Fessi
Journal:  Pharm Res       Date:  1998-07       Impact factor: 4.200

9.  Regulatory considerations for oligonucleotide drugs: updated recommendations for pharmacology and toxicology studies.

Authors:  L E Black; J G Farrelly; J A Cavagnaro; C H Ahn; J J DeGeorge; A S Taylor; A F DeFelice; A Jordan
Journal:  Antisense Res Dev       Date:  1994

10.  Polyalkylcyanoacrylate nanoparticles as polymeric carriers for antisense oligonucleotides.

Authors:  C Chavany; T Le Doan; P Couvreur; F Puisieux; C Hélène
Journal:  Pharm Res       Date:  1992-04       Impact factor: 4.200

View more
  14 in total

1.  Poly(anhydride) nanoparticles act as active Th1 adjuvants through Toll-like receptor exploitation.

Authors:  I Tamayo; J M Irache; C Mansilla; J Ochoa-Repáraz; J J Lasarte; C Gamazo
Journal:  Clin Vaccine Immunol       Date:  2010-07-14

Review 2.  Nanocarriers' entry into the cell: relevance to drug delivery.

Authors:  Hervé Hillaireau; Patrick Couvreur
Journal:  Cell Mol Life Sci       Date:  2009-06-05       Impact factor: 9.261

Review 3.  Methods for the preparation and manufacture of polymeric nanoparticles.

Authors:  Christine Vauthier; Kawthar Bouchemal
Journal:  Pharm Res       Date:  2008-12-24       Impact factor: 4.200

Review 4.  Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA.

Authors:  Elias Fattal; Gillian Barratt
Journal:  Br J Pharmacol       Date:  2009-04-02       Impact factor: 8.739

5.  Efficacy of siRNA nanocapsules targeted against the EWS-Fli1 oncogene in Ewing sarcoma.

Authors:  Nedjma Toub; Jean-Rémi Bertrand; Ali Tamaddon; Hind Elhamess; Hervé Hillaireau; Andrei Maksimenko; Jean Maccario; Claude Malvy; Elias Fattal; Patrick Couvreur
Journal:  Pharm Res       Date:  2006-05-02       Impact factor: 4.200

6.  Nanocapsules: the weapons for novel drug delivery systems.

Authors:  Pavankumar Kothamasu; Hemanth Kanumur; Niranjan Ravur; Chiranjeevi Maddu; Radhika Parasuramrajam; Sivakumar Thangavel
Journal:  Bioimpacts       Date:  2012-04-05

Review 7.  Top-down particle fabrication: control of size and shape for diagnostic imaging and drug delivery.

Authors:  Dorian A Canelas; Kevin P Herlihy; Joseph M DeSimone
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2009 Jul-Aug

8.  Oligonucleotides targeted against a junction oncogene are made efficient by nanotechnologies.

Authors:  Andrei Maksimenko; Claude Malvy; Gregory Lambert; Jean-Rémy Bertrand; Elias Fattal; Jean Maccario; Patrick Couvreur
Journal:  Pharm Res       Date:  2003-10       Impact factor: 4.200

9.  Preparation and characterization of magnetic nanoparticles containing Fe(3)O(4)-dextran-anti-β-human chorionic gonadotropin, a new generation choriocarcinoma-specific gene vector.

Authors:  Cai Jingting; Liu Huining; Zhang Yi
Journal:  Int J Nanomedicine       Date:  2011-02-02

Review 10.  Polymeric particulates to improve oral bioavailability of peptide drugs.

Authors:  Florence Delie; María José Blanco-Príeto
Journal:  Molecules       Date:  2005-01-31       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.